Thalassemia
2 papers
- In silico1
Trial sponsors
Novartis Pharmaceuticals Corporation
Company2 trialsPhase 4339 people
Company1 trialPhase 270 people
Fakultas Kedokteran Universitas Indonesia
2 trialsPhase 4114 people
2 trialsPhase 4114 people
1 trialPhase 460 people
University of Campinas, Brazil
1 trialPhase 362 people
1 trialPhase 2/3654 people
Masonic Cancer Center, University of Minnesota
1 trialPhase 2/322 people
Funding
1 grant since 2023National Heart, Lung, and Blood InstituteUS$1.9m
Latest
5 in 12 monthsmedRxiv
Clinically Translatable Uncertainty Aware Machine Learning for Cardiovascular Disease Risk Analysis
Preprint: computational studyCardiovascular disease
Frontiers in Medical Technology
A comparative performance analysis of ensemble learning and regularized neural networks in cardiovascular risk prediction
Computational studyCardiovascular disease
Mediterranean Journal of Hematology and Infectious Diseases
Aging with Thalassemia and Sickle Cell Disease: A Gerontological Model of Accelerated Multimorbidity and Function-Centered Care Beyond Midlife
ReviewMechanisms
Journal of the American Heart Association
Age-Associated Increase in Growth Differentiation Factor 15 Levels Correlates With Central Arterial Stiffness and Predicts All-Cause Mortality in a Sardinian Population Cohort
Cohort study of 4,736 peopleArterial stiffness
The Journals of Gerontology, Series A
Black Americans With Sickle Cell Disease (SCD) Demonstrate Accelerated Epigenetic Pace of Aging Compared to Black Americans Without SCD
Study in peopleBiomarkers
Journal of Cellular and Molecular Medicine
Effects of Sirolimus treatment on patients with β-Thalassemia: Lymphocyte immunophenotype and biological activity of memory CD4⁺ and CD8⁺ T cells
Trial in peopleInterventions